Eli Lilly and Co (NYSE:LLY) Stock News, Headlines & Updates
Eli Lilly and Co Stock News from GuruFocus
- 1
- 2
- 3
- 4
- 5
Jun 30, 2025
Eli Lilly (LLY) Faces Rising Competition from Innovent Biologics
GuruFocus News • 8:58am
Jun 26, 2025
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1.3 Billion Deal | LLY Stock News
GuruFocus News • 4:45pm
Eli Lilly (LLY) Expands Mounjaro in India, Competing with Novo Nordisk
GuruFocus News • 5:55am
Jun 25, 2025
Eli Lilly (LLY): Rising Adherence to GLP-1 Treatments in 2024
GuruFocus News • 9:58am
Eli Lilly (LLY) Poised for Growth in Emerging Obesity Market | LLY Stock News
GuruFocus News • 5:49am
Jun 24, 2025
Eli Lilly's (LLY) Olomorasib Gains Orphan Drug Status for Lung Cancer Treatment
GuruFocus News • 5:55pm
Eli Lilly (LLY) Gains FDA Orphan Status for KRAS G12C-Mutant NSCLC Drug | LLY Stock News
GuruFocus News • 2:15pm
California Cuts Medicaid Coverage for Eli Lilly's (LLY) Weight Loss Drug | LLY Stock News
GuruFocus News • 8:45am
Jun 23, 2025
Eli Lilly and Co (LLY) Announces Third Quarter 2025 Dividend | LLY stock news
GuruFocus News • 12:02pm
Eli Lilly (LLY) Maintains Quarterly Dividend at $1.50
GuruFocus News • 11:55am
Eli Lilly (LLY) Shows Promising Results in Diabetes Treatment Trials | LLY Stock News
GuruFocus News • 11:24am
Eli Lilly (LLY) Announces Promising Phase 3 Trial Results for Diabetes Drug | LLY Stock News
GuruFocus News • 11:19am
Eli Lilly's (LLY) Zepbound Faces New Competition from Ecnoglutide | LLY Stock News
GuruFocus News • 11:19am
Lilly declares third-quarter 2025 dividend
PRNewswire • 11:00am
Eli Lilly's (LLY) Bimagrumab Shows Promising Weight Loss Results
GuruFocus News • 10:57am
Eli Lilly's (LLY) Insulin Efsitora Shows Promise in Phase 3 Trials
GuruFocus News • 10:55am
Lilly declares third-quarter 2025 dividend | LLY Stock News
GuruFocus News • 10:45am
Jun 22, 2025
Eli Lilly's Efsitora Alfa Shows Promising Results in Phase 3 Trials | LLY stock news
GuruFocus News • 2:01pm
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
PRNewswire • 2:00pm
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials | LLY Stock News
GuruFocus News • 1:45pm
Eli Lilly (LLY) to Acquire Verve Therapeutics in $1.3B Deal
GuruFocus News • 8:55am
Jun 21, 2025
Eli Lilly (LLY) Achieves Key Results in Phase 3 Diabetes Trial
GuruFocus News • 9:55am
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medici
GuruFocus News • 8:15am
Jun 20, 2025
Eli Lilly (LLY) to Reveal Key Phase 3 Trial Results for Orforglipron
GuruFocus News • 2:55pm
Eli Lilly (LLY) Gains Boost from New Obesity Drug Recommendations
GuruFocus News • 12:55pm
Eli Lilly (LLY) Maintains Buy Rating and Price Target at $936 | LLY Stock News
GuruFocus News • 9:30am
Eli Lilly (LLY) to Appeal UK Rejection of Alzheimer's Drug Kisunla
GuruFocus News • 6:57am
Eli Lilly (LLY) Sees Strong Demand for Mounjaro in India | LLY Stock News
GuruFocus News • 5:48am
Jun 18, 2025
Eli Lilly (LLY): Bariatric Surgery Outperforms GLP-1 Drugs in Weight Loss Study
GuruFocus News • 9:55am
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal | LLY Stock News
GuruFocus News • 4:31am
Jun 17, 2025
Eli Lilly (LLY) to Acquire Verve Therapeutics in $1.3 Billion Deal | LLY Stock News
GuruFocus News • 6:15am
Eli Lilly and Co (LLY) to Acquire Verve Therapeutics for Cardiovascular Gene Editing Advancements | LLY stock news
GuruFocus News • 6:05am
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | LLY Stock News
GuruFocus News • 6:00am
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
PRNewswire • 6:00am
Eli Lilly (LLY) Nears $1.3B Acquisition Deal for Verve Therapeutics
GuruFocus News • 3:56am
Jun 16, 2025
Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co
GuruFocus News • 12:00pm
Eli Lilly (LLY) Expands Zepbound Availability Directly to Consumers
GuruFocus News • 6:58am
Eli Lilly (LLY) Introduces New Doses of Zepbound for Direct Purchase | LLY Stock News
GuruFocus News • 6:17am
Eli Lilly and Co (LLY) Expands Zepbound Availability with New Single-Dose Vials | LLY stock news
GuruFocus News • 6:02am
- 1
- 2
- 3
- 4
- 5
Show
Entries
Headlines
Total 0- 1
No recent news